SEC Comment Letter for EAGLE PHARMACEUTICALS, INC. (EGRX) (CIK 0000827871) — Feb 21, 2020
EAGLE PHARMACEUTICALS, INC. (EGRX) (CIK 0000827871)
Date: Feb. 21, 2020 · CIK: 0000827871 · Accession: 0000000000-20-001613
AI Filing Summary & Sentiment
File numbers found in text: 001-36306
Letter
February 21, 2020 Pete Meyers Chief Financial Officer Eagle Pharmaceuticals, Inc. 50 Tice Boulevard, Suite 315 Woodcliff Lake, NJ 07677 Re:Eagle Pharmaceuticals, Inc. Form 10-K for the fiscal year ended December 31, 2018 Filed February 28, 2019 File No. 001-36306 Dear Mr. Meyers: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
February 21, 2020
Pete Meyers
Chief Financial Officer
Eagle Pharmaceuticals, Inc.
50 Tice Boulevard, Suite 315
Woodcliff Lake, NJ 07677
Re:Eagle Pharmaceuticals, Inc.
Form 10-K for the fiscal year ended December 31, 2018
Filed February 28, 2019
File No. 001-36306
Dear Mr. Meyers:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences